Our number one priority is to ensure patients continue to have unhindered access to medicines as we exit the European Union and we are working with all sectors in the supply chain to ensure this happens.<\/p>
<\/p>
We understand that medicines for rheumatoid arthritis are vitally important to many people in this country. Our \u2018no deal\u2019 medicines supply contingency plans include sensible mitigations for medicines that come to the United Kingdom from or via the EU/European Economic Area (EEA) to ensure that the supply of essential medicines, including medicines for patients with rheumatoid arthritis, is not disrupted.<\/p>
<\/p>
In August 2018, the Department wrote to all pharmaceutical companies that supply prescription-only and pharmacy medicines, including those for rheumatoid arthritis, to the UK that come from, or via, the EU/EEA asking them to ensure a minimum of six weeks\u2019 additional supply in the UK, over and above existing business-as-usual buffer stocks, by 29 March 2019.<\/p>
<\/p>
On 7 December, the Government published updated reasonable worst-case scenario border disruption planning assumptions in the event of a \u2018no deal\u2019 EU exit. Medicines and medical products are prioritised in cross-Government planning, and the Department is working with relevant partners across Government and industry to ensure we have sufficient roll-on, roll-off freight capacity on alternative routes to enable these vital products to continue to move freely into the UK.<\/p>
<\/p>
Throughout enacting our plans, we have received very good engagement from industry, including on their plans to stockpile medicines. They share our aims of ensuring that the continuity of supply of medicines and medical products for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a \u2018no deal\u2019 EU exit.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"} } , "answeringMemberConstituency" : {"_value" : "Wimbledon"} , "answeringMemberPrinted" : {"_value" : "Stephen Hammond"} , "dateOfAnswer" : {"_value" : "2019-02-14", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "219497"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-02-14T17:06:21.49Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-02-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Arthritis: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the supply of medications for rheumatoid arthritis in the event that the UK leaves the EU without a deal.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4463", "label" : {"_value" : "Biography information for Chris Stephens"} } , "tablingMemberConstituency" : {"_value" : "Glasgow South West"} , "tablingMemberPrinted" : [{"_value" : "Chris Stephens"} ], "uin" : "219496"} , {"_about" : "http://data.parliament.uk/resources/1058976", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1058976/answer", "answerText" : {"_value" : "
Our number one priority is to ensure patients continue to have unhindered access to medicines as we exit the European Union and we are working with all sectors in the supply chain to ensure this happens.<\/p>
<\/p>
We understand that medicines for rheumatoid arthritis are vitally important to many people in this country. Our \u2018no deal\u2019 medicines supply contingency plans include sensible mitigations for medicines that come to the United Kingdom from or via the EU/European Economic Area (EEA) to ensure that the supply of essential medicines, including medicines for patients with rheumatoid arthritis, is not disrupted.<\/p>
<\/p>
In August 2018, the Department wrote to all pharmaceutical companies that supply prescription-only and pharmacy medicines, including those for rheumatoid arthritis, to the UK that come from, or via, the EU/EEA asking them to ensure a minimum of six weeks\u2019 additional supply in the UK, over and above existing business-as-usual buffer stocks, by 29 March 2019.<\/p>
<\/p>
On 7 December, the Government published updated reasonable worst-case scenario border disruption planning assumptions in the event of a \u2018no deal\u2019 EU exit. Medicines and medical products are prioritised in cross-Government planning, and the Department is working with relevant partners across Government and industry to ensure we have sufficient roll-on, roll-off freight capacity on alternative routes to enable these vital products to continue to move freely into the UK.<\/p>
<\/p>
Throughout enacting our plans, we have received very good engagement from industry, including on their plans to stockpile medicines. They share our aims of ensuring that the continuity of supply of medicines and medical products for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a \u2018no deal\u2019 EU exit.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"} } , "answeringMemberConstituency" : {"_value" : "Wimbledon"} , "answeringMemberPrinted" : {"_value" : "Stephen Hammond"} , "dateOfAnswer" : {"_value" : "2019-02-14", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "219496"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-02-14T17:06:21.567Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-02-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to (a) protect patients and (b) ensure pharmaceutical companies have a minimum of six weeks\u2019 additional supply of vital medications over and above existing business-as-usual buffer stocks in the event that the UK leaves the EU without a deal.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4463", "label" : {"_value" : "Biography information for Chris Stephens"} } , "tablingMemberConstituency" : {"_value" : "Glasgow South West"} , "tablingMemberPrinted" : [{"_value" : "Chris Stephens"} ], "uin" : "219497"} , {"_about" : "http://data.parliament.uk/resources/1035347", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1035347/answer", "answerText" : {"_value" : "
Delivering the deal negotiated with the European Union remains the Government\u2019s top priority. This has not changed. However, the Government must prepare for every eventuality.<\/p>
<\/p>
Given the interactions between EU exit work and the Department\u2019s other priorities, it is not possible to provide an accurate break-down of the additional staff required in the event of deal and no-deal exit scenarios specifically.<\/p>
<\/p>
The resources available are under constant review and the Department is equipping itself with the resources it needs to deliver a smooth and orderly exit from the EU.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"} } , "answeringMemberConstituency" : {"_value" : "Wimbledon"} , "answeringMemberPrinted" : {"_value" : "Stephen Hammond"} , "dateOfAnswer" : {"_value" : "2019-01-14", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-01-14T16:01:49.377Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-01-04", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Department of Health: Brexit"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what estimate he has made of the additional staff required by his Department in the event that the UK leaves the EU (a) with and (b) without a deal.", "registeredInterest" : {"_value" : "true", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4463", "label" : {"_value" : "Biography information for Chris Stephens"} } , "tablingMemberConstituency" : {"_value" : "Glasgow South West"} , "tablingMemberPrinted" : [{"_value" : "Chris Stephens"} ], "uin" : "205315"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 3, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }